- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18:08 | Sun Pharma the latest to recall metformin after carcinogen tests come up positive | ||
| 18:08 | ICER rubber-stamps Vertex's $311K CF drug Trikafta but blasts 'monopoly' pricing | ||
| 17:08 | Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan | ||
| 16:42 | Humanigen, Thermo Fisher strike deal to scale up manufacturing of monoclonal antibody for COVID-19 | ||
| 16:42 | Novartis' Zolgensma expansion hits FDA roadblock, giving Biogen and Roche a reprieve | ||
| Di | Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week | ||
| Di | How will BMS' new Opdivo-Cabometyx kidney cancer combo fare against Keytruda? It may come down to marketing: analyst | ||
| Di | Former Biogen CFO Capello scores $2.6M payment plus full severance benefits on his way out | ||
| Di | Pharma TV spending bounced back with pro sports in August, with AbbVie, Regeneron/Sanofi leading the way | ||
| Di | AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push | ||
| Di | Viral vector manufacturer Vibalogics adds CEO to lead expansion, COVID-19 response | ||
| Mo | ESMO: Merck's Keytruda pushes for second esophageal cancer nod with first-line survival win | ||
| Mo | ESMO: Bristol Myers' Opdivo racks up GI cancer data for two potentially practice-changing FDA nods | ||
| Mo | Chinese customs raids J&J CAR-T partner Legend's office, puts new CEO under 'residential surveillance' | ||
| Mo | FiercePharmaPolitics-White House, pharma pricing talks fell apart over demand for 'Trump Cards': NYT | ||
| Mo | ESMO: Merck's Keytruda doubles 5-year survival rate for lung cancer patients | ||
| So | ESMO: AstraZeneca, Merck's Lynparza boosts prostate cancer survival by 31% over J&J, Pfizer-Astellas rivals | ||
| So | ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show | ||
| Sa | ESMO: Bristol Myers preps 2nd kidney cancer combo nod as Opdivo-Cabometyx duo slashes death risk 40% | ||
| Sa | ESMO: New Trodelvy breast, bladder cancer data show why Gilead's going big for Immunomedics | ||
| Sa | ESMO: Merck's Keytruda matches Opdivo on key survival metric for post-surgery melanoma | ||
| Sa | ESMO: Pfizer's Ibrance flop in early breast cancer shouldn't hurt metastatic sales, exec says | ||
| Sa | ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial | ||
| Fr | Astellas, Seattle Genetics' Padcev bladder cancer trial stops early with 30% death risk reduction | ||
| Fr | Biogen stands to lose billions in Tecfidera sales next year, analyst says after new court ruling |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
